NasdaqCM - Delayed Quote USD

Unicycive Therapeutics, Inc. (UNCY)

1.1300

+0.0500

(+4.63%)

At close: May 10 at 4:00 PM EDT

1.1400

+0.01

(+0.88%)

After hours: May 10 at 5:46 PM EDT

Key Events

Loading Chart for UNCY

9/21 12:03 PM

DELL

Previous Close 1.0800
Open 1.0701
Bid 1.1100 x 500
Ask 1.1500 x 400
Day's Range 1.0500 - 1.1400
52 Week Range 0.4700 - 1.8230
Volume 276,687
Avg. Volume 415,696
Market Cap (intraday) 42.495M
Beta (5Y Monthly) 2.71
PE Ratio (TTM) --
EPS (TTM) -1.2800
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 5.30

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

14

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

UNCY

30.18%

S&P 500

9.49%

1-Year Return

UNCY

25.66%

S&P 500

26.79%

3-Year Return

UNCY

--

S&P 500

19.11%

5-Year Return

UNCY

--

S&P 500

19.11%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Unicycive Therapeutics, Inc.

1.1300

+4.63%

Mkt Cap 42.495M

Industry Biotechnology

Taysha Gene Therapies, Inc.

2.3400

-7.51%

Mkt Cap 437.622M

Industry Biotechnology

0.2160

-13.08%

Mkt Cap 6.222M

Industry Biotechnology

Regulus Therapeutics Inc.

2.2100

-1.78%

Mkt Cap 144.678M

Industry Biotechnology

0.3865

-0.13%

Mkt Cap 49.64M

Industry Biotechnology

Aligos Therapeutics, Inc.

0.7303

-5.95%

Mkt Cap 57.044M

Industry Biotechnology

0.7713

-4.14%

Mkt Cap 39.304M

Industry Biotechnology

Cellectar Biosciences, Inc.

3.0700

-5.25%

Mkt Cap 110.056M

Industry Biotechnology

Inhibikase Therapeutics, Inc.

1.3100

-4.38%

Mkt Cap 8.485M

Industry Biotechnology

Zura Bio Limited

4.6800

+1.74%

Mkt Cap 291.686M

Industry Biotechnology

Connect Biopharma Holdings Limited

1.5000

+4.90%

Mkt Cap 82.654M

Industry Biotechnology

Valuation Measures

As of 5/10/2024

Market Cap

42.50M
Enterprise Value

33.61M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

41.08
Price/Book (mrq)

--
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-152.67%
Return on Equity (ttm)

--
Revenue (ttm)

675k
Net Income Avi to Common (ttm)

-31.41M
Diluted EPS (ttm)

-1.2800

Balance Sheet and Cash Flow

Total Cash (mrq)

9.7M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

1.57M

UNCY does not have Company Insights

ELEV Elevation Oncology, Inc.

3.2800

-6.55%

RNAZ TransCode Therapeutics, Inc.

1.4100

+6.02%

DRMA Dermata Therapeutics, Inc.

0.3587

+10.85%

INAB IN8bio, Inc.

1.0100

-0.98%

CDIO Cardio Diagnostics Holdings, Inc.

0.9052

+24.10%

VRAX Virax Biolabs Group Limited

0.8000

+8.14%

PALI Palisade Bio, Inc.

6.71

-3.31%

ENSC Ensysce Biosciences, Inc.

0.5240

-5.42%

PXMD PaxMedica, Inc.

0.2070

-13.32%

JSPR Jasper Therapeutics, Inc.

21.33

-0.42%

HSCS Heart Test Laboratories, Inc.

0.0880

-2.11%

FWBI First Wave BioPharma, Inc.

2.8500

-0.35%

KPRX Kiora Pharmaceuticals, Inc.

0.4862

-0.16%

CING Cingulate Inc.

0.7610

-14.49%

VLON Vallon Pharmaceuticals Inc.

0.4000

-13.04%

CNTX Context Therapeutics Inc.

1.8700

+2.19%